Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Northwestern University — Chicago, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Illinois — Chicago, Illinois
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Illinois: - Rush-Copley Medical Center — Aurora, Illinois
- Advocate Good Shepherd Hospital — Barrington, Illinois
- Mount Sinai Hospital Medical Center — Chicago, Illinois
- Lurie Children's Hospital-Chicago — Chicago, Illinois
- Northwestern University — Chicago, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Illinois: - Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- Alliance for Clinical Trials in Oncology — Chicago, Illinois
- University of Illinois — Chicago, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of vorasidenib to placebo in combination with usual treatment, temozolomide, in treating patients with newly diagnosed grade 3 astrocytoma after radiation. Temozolomide is in a class of medications …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07215910
Sites in Illinois: - OSF Saint Joseph Medical Center — Bloomington, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Illinois CancerCare-Carthage — Carthage, Illinois
- University of Illinois — Chicago, Illinois
Phase 3 Recruiting Industry
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…
Sponsor: BeOne Medicines
NCT ID: NCT05100862
Sites in Illinois: - Cancer Care Specialists of Illinois — Decatur, Illinois
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…
Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago (Adults and Pediatrics) — Chicago, Illinois
- University of Chicago Medical Center - Duchossois Center for Advanced Medicine (Adults only) — Chicago, Illinois
- Loyola University Medical Center (Adults and Pediatrics) — Maywood, Illinois
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in Illinois: - Local Institution - 0240 — Arlington Heights, Illinois
Phase 2, Phase 3 Recruiting Industry
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT05139017
Sites in Illinois: - Illinois Cancer Specialists ( Site 8000) — Niles, Illinois
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- OSF Children's Hospital of Illinois — Peoria, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois
- Advocate Children's Hospital-Park Ridge — Park Ridge, Illinois
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois
- Advocate Children's Hospital-Park Ridge — Park Ridge, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05963074
Sites in Illinois: - Hope and Healing Cancer Services — Hinsdale, Illinois
- Springfield Clinic — Springfield, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
Phase 2 Recruiting Academic/Other
This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…
Sponsor: Etan Orgel
NCT ID: NCT05082519
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
Sponsor: Kite, A Gilead Company
NCT ID: NCT04989803
Sites in Illinois: - Midwestern Regional Medical Center, Inc.City of Hope Chicago — Park Ridge, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate t…
Sponsor: Cellectis S.A.
NCT ID: NCT04150497
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have recei…
Sponsor: AstraZeneca
NCT ID: NCT06137118
Sites in Illinois: - Research Site — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid mali…
Sponsor: AVM Biotechnology Inc
NCT ID: NCT04329728
Sites in Illinois: - University of Illinois at Chicago Cancer Center — Chicago, Illinois
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a trea…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT03824483
Sites in Illinois: - Northwestern University — Evanston, Illinois
Phase 1, Phase 2 Recruiting Industry
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be remove…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT02332668
Sites in Illinois: - Call for Information (Investigational Site 0024) — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with…
Sponsor: AstraZeneca
NCT ID: NCT07155226
Sites in Illinois: - Research Site — Decatur, Illinois
Phase 1, Phase 2 Recruiting Industry
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, wh…
Sponsor: AvenCell Therapeutics, Inc.
NCT ID: NCT07284433
Sites in Illinois: - University of Chicago — Chicago, Illinois
- Northwestern University — Evanston, Illinois
Phase 2 Recruiting Academic/Other
This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not responded to initial treatment (refracto…
Sponsor: City of Hope Medical Center
NCT ID: NCT04561206
Sites in Illinois: - University of Chicago Cancer Research Center — Chicago, Illinois